Clinical Trials
393
10 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1936
Active, not recruiting
5
1.3%
Completed
113
28.8%
Not yet recruiting
5
1.3%
Recruiting
30
7.6%
Suspended
1
0.3%
Terminated
26
6.6%
Unknown
193
49.1%
Withdrawn
20
5.1%
No approval data available
- Omnix Medical has dosed the first patients in a Phase II trial of OMN6, a first-in-class antimicrobial targeting severe multidrug-resistant Acinetobacter baumannii infections with mortality rates up to 60%. - OMN6 employs a novel membrane-disrupting mechanism that rapidly forms pores in bacterial membranes, leading to direct physical destruction of pathogens while minimizing resistance development potential. - The Phase IIa study is a randomized, double-blind, placebo-controlled trial evaluating OMN6 in patients with hospital-acquired or ventilator-associated bacterial pneumonia caused by carbapenem-resistant strains. - The WHO has classified Acinetobacter baumannii as a critical priority pathogen, highlighting the urgent need for novel anti-infective approaches with differentiated mechanisms of action.
- Can-Fite BioPharma received Institutional Review Board approval from Rabin Medical Center to initiate a Phase IIa open-label study evaluating Namodenoson in advanced pancreatic adenocarcinoma patients. - The multicenter trial will enroll approximately 20 patients with disease progression on first-line therapy, administering oral Namodenoson 25 mg twice daily in 28-day cycles. - Namodenoson demonstrated efficacy in preclinical pancreatic cancer models through deregulation of Wnt/β-catenin, NF-κB, and RAS signaling pathways. - The A3 adenosine receptor-targeting drug has shown promising results in liver cancer, with one patient achieving complete response lasting over 7 years.
- Early research suggests CBD may help curb SARS-CoV-2 replication in infected cells, warranting further investigation through rigorous clinical trials. - Studies indicate CBD acts post-infection, blocking virus replication, while THC and other cannabinoids do not show the same antiviral effects. - Researchers emphasize that current evidence does not support self-medication with CBD and highlight the importance of vaccines and antibody drugs. - Clinical trials are underway to assess CBD's efficacy in treating COVID-19, with challenges in enrolling patients due to milder Omicron cases.
